AU2002251329A1 - Novel crystalline forms of celecoxib and other compounds - Google Patents

Novel crystalline forms of celecoxib and other compounds

Info

Publication number
AU2002251329A1
AU2002251329A1 AU2002251329A AU2002251329A AU2002251329A1 AU 2002251329 A1 AU2002251329 A1 AU 2002251329A1 AU 2002251329 A AU2002251329 A AU 2002251329A AU 2002251329 A AU2002251329 A AU 2002251329A AU 2002251329 A1 AU2002251329 A1 AU 2002251329A1
Authority
AU
Australia
Prior art keywords
celecoxib
compounds
crystalline forms
novel crystalline
novel
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002251329A
Inventor
Elias Ndzie
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Generics UK Ltd
Original Assignee
Generics UK Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Generics UK Ltd filed Critical Generics UK Ltd
Publication of AU2002251329A1 publication Critical patent/AU2002251329A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Rheumatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2002251329A 2002-04-25 2002-04-25 Novel crystalline forms of celecoxib and other compounds Abandoned AU2002251329A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/GB2002/001902 WO2003090730A1 (en) 2002-04-25 2002-04-25 Novel crystalline forms of celecoxib and other compounds

Publications (1)

Publication Number Publication Date
AU2002251329A1 true AU2002251329A1 (en) 2003-11-10

Family

ID=29266190

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002251329A Abandoned AU2002251329A1 (en) 2002-04-25 2002-04-25 Novel crystalline forms of celecoxib and other compounds

Country Status (2)

Country Link
AU (1) AU2002251329A1 (en)
WO (1) WO2003090730A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL373191A1 (en) 2002-04-29 2005-08-22 Teva Gyogyszergyar Reszvenytarsasag Process for preparing 1,2,3,9-tetrahydro-9-methyl-3-[(2-methyl-1h-imidazol-1-yl)methyl]-4h-carbazol-4-one

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA74539C2 (en) * 1999-12-08 2006-01-16 Pharmacia Corp Crystalline polymorphous forms of celecoxib (variants), a method for the preparation thereof (variants), a pharmaceutical composition (variants)
TR200001872A3 (en) * 2000-06-26 2002-01-21 Fako Ilaclari A.S The new crystal form "Form I" of 4- [5- (4-Methylphenyl-3- (trifluoromethyl) -1H-pyrazol-1-yl] benzenesulfonamide and the method for producing this product.
BR0114031A (en) * 2000-08-31 2003-09-09 Reddy S Lab Ltd Process for the preparation of olanzapine hydrates and their conversion to crystalline forms of olanzapine
CN1152865C (en) * 2000-09-18 2004-06-09 中国科学院广州化学研究所 Synthesis of sylekirsey
IL139243A0 (en) * 2000-10-24 2001-11-25 Internat Specialty Products Is Ethanolate of zafirlukast, process for manufacture and pharmaceutical compositions thereof

Also Published As

Publication number Publication date
WO2003090730A1 (en) 2003-11-06

Similar Documents

Publication Publication Date Title
AU2003239644A1 (en) Crystallization of sugars
AU2003202924A1 (en) Variation of neural-stimulation parameters
AU2003301451A1 (en) Component capable of being cooled
AU2003230192A1 (en) Novel crystalline forms of aripiprazole
AU2003245572A1 (en) Preparation of chiral amino-nitriles
AU2003243926A1 (en) Stabilization of granules
AU2002330453A1 (en) Crystals of hydroxynorephedrine derivative
AU2003220068A1 (en) Molecular crystals of controlled size
AU2003255551A1 (en) Characterisation of paper
AU2003230844A1 (en) Crystals and structures of pak4kd kinase pak4kd
AU2003224781A1 (en) Crystalline forms of rabeprazole sodium
AU2003265373A1 (en) Preparation of aztreonam
AU2003246963A1 (en) Synthesis of cyclohexanone derivatives
AU2003217438A1 (en) Novel crystalline forms of levetiracetam
AU2003262141A1 (en) Preperation of desloratatine
AU2002251329A1 (en) Novel crystalline forms of celecoxib and other compounds
AU2003298725A1 (en) Preparation of metallotexaphyrins
AU2003257541A1 (en) Novel crystals
AU2003266408A1 (en) Multi-signal determination of polarization dependent characteristic
AU2003217437A1 (en) Novel crystalline forms of lamotrigine
AU2003264861A1 (en) Novel crystalline forms of celecoxib
AU2003238034A1 (en) Novel use of imidazotriazinones
EP1486485A4 (en) Novel crystals of 5-hydroxycarbamimidoyl-2-hydroxybenzenesulfonamide derivative
AU2003238668A1 (en) Novel crystalline forms of valdecoxib
AU2003299746A1 (en) Total synthesis of daurichromenic acid

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase